GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daewoong Pharmaceutical Co Ltd (XKRX:069620) » Definitions » EV-to-Revenue

Daewoong Pharmaceutical Co (XKRX:069620) EV-to-Revenue : 1.14 (As of Jun. 04, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Daewoong Pharmaceutical Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Daewoong Pharmaceutical Co's enterprise value is ₩1,584,487 Mil. Daewoong Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ₩1,388,699 Mil. Therefore, Daewoong Pharmaceutical Co's EV-to-Revenue for today is 1.14.

The historical rank and industry rank for Daewoong Pharmaceutical Co's EV-to-Revenue or its related term are showing as below:

XKRX:069620' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.74   Med: 1.42   Max: 2.67
Current: 1.14

During the past 13 years, the highest EV-to-Revenue of Daewoong Pharmaceutical Co was 2.67. The lowest was 0.74. And the median was 1.42.

XKRX:069620's EV-to-Revenue is ranked better than
75.12% of 1021 companies
in the Drug Manufacturers industry
Industry Median: 2.29 vs XKRX:069620: 1.14

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-04), Daewoong Pharmaceutical Co's stock price is ₩107300.00. Daewoong Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ₩120,701.30. Therefore, Daewoong Pharmaceutical Co's PS Ratio for today is 0.89.


Daewoong Pharmaceutical Co EV-to-Revenue Historical Data

The historical data trend for Daewoong Pharmaceutical Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daewoong Pharmaceutical Co EV-to-Revenue Chart

Daewoong Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.62 2.07 1.77 1.71 1.30

Daewoong Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.23 1.13 1.26 1.30 1.36

Competitive Comparison of Daewoong Pharmaceutical Co's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Daewoong Pharmaceutical Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daewoong Pharmaceutical Co's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daewoong Pharmaceutical Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Daewoong Pharmaceutical Co's EV-to-Revenue falls into.



Daewoong Pharmaceutical Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Daewoong Pharmaceutical Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1584487.331/1388699.36
=1.14

Daewoong Pharmaceutical Co's current Enterprise Value is ₩1,584,487 Mil.
Daewoong Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩1,388,699 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daewoong Pharmaceutical Co  (XKRX:069620) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Daewoong Pharmaceutical Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=107300.00/120701.303
=0.89

Daewoong Pharmaceutical Co's share price for today is ₩107300.00.
Daewoong Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩120,701.30.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daewoong Pharmaceutical Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Daewoong Pharmaceutical Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Daewoong Pharmaceutical Co (XKRX:069620) Business Description

Traded in Other Exchanges
N/A
Address
12, Bongeunsa-ro 114-gil, Daewoong Pharmaceutical Building, Gangnam-gu, Seoul, KOR
Daewoong Pharmaceutical Co Ltd develops, manufactures and sells prescription drug products. The company's product portfolio comprises products such as Moxicle, Plunazol Cap, Bearcef tab, Newdizime etc. It develops and promotes brands such as Ursa, Nabota, Luphere, Easyef, Cretropin. The company has manufacturing facilities at Hyangnam and Sungnam.

Daewoong Pharmaceutical Co (XKRX:069620) Headlines

No Headlines